The impact of COVID-19 pandemic on psoriasis patients, and their immunosuppressive treatment: a cross-sectional multicenter study from Turkey

References

• Conforti C, Giuffrida R, Dianzani C, et al. COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action. Dermatol Ther. 2020; 33:e13298.
   PubMed Web of Science ®Google Scholar
• Niaki OZ, Anadkat MJ, Chen ST, et al. Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. J Am Acad Dermatol. 2020;83:1150–1159.
   PubMed Web of Science ®Google Scholar
• National Psoriasis Foundation. NPF Forms COVID-19 Task Force. 2020. https://www.psoriasis.org/advance/coronavirus. Accessed on January 20, 2021.
   Google Scholar
• European Academy of Dermatology and Venereology. Management of Psoriasis Under Systemic Treatments. 2020. https://www.eadv.org/cms-admin/showfile/7_PSORİASİS-SPIN%20TF%20Recommendations_Covid-Corner.pdf. Accessed on January 20, 2020.
   Google Scholar
• Reynolds SD, Mathur AN, Chiu YE, et al. Systemic immunosuppressive therapy for inflammatory skin diseases in children: Expert consensus‐based guidance for clinical decision‐making during the COVID‐19 pandemic. Pediatr Dermatol. 2020;37:424–434.
   PubMed Web of Science ®Google Scholar
• Michaud K, Wipfler K, Shaw Y, et al. Experiences of patients with rheumatic diseases in the United States during early days of the COVID-19 pandemic. ACR Open Rheumatol. 2020;2:335–343.
   PubMedGoogle Scholar
• Kartal SP, Çelik G, Sendur N, et al. Multicenter study evaluating the impact of COVID‐19 outbreak on dermatology outpatients in Turkey. Dermatol Ther. 2020;33:e14485.
   PubMed Web of Science ®Google Scholar
• COVID-19 Treatment Guidelines - Clinical Spectrum of SARS-CoV-2 infection. https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/#:∼:text = Patients%20with%20COVID%2D19%20are,may%20experience%20rapid%20clinical%20deterioration. Accessed 20 February 2021.
   Google Scholar
• World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 173. 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200711-covid-19-sitrep-173.pdf?sfvrsn=949920b4_2.Accessed. 20 February 2021.
   Google Scholar
• Carroll CL, Feldman SR, Camacho FT, et al. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol. 2004;151(4):895–897.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Zhang J, Martinez DJ, et al. Real-world biologic and apremilast treatment patterns and healthcare costs in moderate-to-severe plaque psoriasis. Dermatol Online J. 2021;27. 13030/qt03t0s9j6.
   Google Scholar
• Esposito M, Gisondi P, Cassano N, et al. Survival rate of antitumour necrosis factor-alpha treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol. 2013;169(3):666–672.
   PubMed Web of Science ®Google Scholar
• Dommasch ED, Lee MP, Joyce CJ, et al. Drug utilization patterns and adherence in patients on systemic medications for the treatment of psoriasis: a retrospective, comparative cohort study. J Am Acad Dermatol. 2018;79(6):1061–1068.e1.
   PubMed Web of Science ®Google Scholar
• Rob F, Hugo J, Tivadar S, et al. Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID‐19 pandemic national lockdown: a multicenter study in the Czech Republic. J Eur Acad Dermatol Venereol. 2020;34:e682–e684.
   PubMed Web of Science ®Google Scholar
• Tilotta G, Pistone G, Caruso P, et al. Adherence to biological therapy in dermatological patients during the COVID‐19 pandemic in Western Sicily. Int J Dermatol. 2021;60:248–249.
   PubMed Web of Science ®Google Scholar
• Carugno A, Gambini DM, Raponi F, et al. COVID-19 and biologics for psoriasis: A high-epidemic area experience—Bergamo, Lombardy, Italy. J Am Acad Dermatol. 2020;83(1):292–294.
   PubMed Web of Science ®Google Scholar
• Vangeli E, Bakhshi S, Baker A, et al. A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther. 2015; 32:983–1028.
   PubMed Web of Science ®Google Scholar
• Kretchy IA, Asiedu-Danso M, Kretchy JP. Medication management and adherence during the COVID-19 pandemic: perspectives and experiences from low-and middle-income countries. Res Soc Admin Pharm. 2021;17(1):2023–2026.
   PubMed Web of Science ®Google Scholar
• O’Leary A, Urbaniak A, Phelan M, et al. Compliance with immunosuppression for rheumatic disease during the COVID-19 pandemic. Ir Med J. 2020;113:170–171.
   Google Scholar
• Vakirlis E, Bakirtzi K, Papadimitriou I, et al. Treatment adherence in psoriatic patients during COVID‐19 pandemic: real‐world data from a tertiary hospital in Greece. J Eur Acad Dermatol Venereol. 2020;34:e673–e675.
   PubMed Web of Science ®Google Scholar
• Khan SS, Marshall CL, Stylianou KA, et al. An evaluation of dermatology patients shielding during the COVID‐19 outbreak. Clin Exp Dermatol. 2021;46:193–194.
   PubMed Web of Science ®Google Scholar
• Burlando M, Carmisciano L, Cozzani E, et al. A survey of psoriasis patients on biologics during COVID-19: a single centre experience. J Dermatol Treat. 2020; 1:1.
   Google Scholar
• Chiricozzi A, Talamonti M, Simone CD, et al. Management of patients with atopic dermatitis undergoing systemic therapy during COVID‐19 pandemic in Italy: data from the DA‐COVID‐19 registry. Allergy. 2021:1–12.
   PubMed Web of Science ®Google Scholar
• Kara Polat A, Oguz Topal I, Karadag AS, et al. The impact of COVID‐19 in patients with psoriasis: A multicentre study in Istanbul. Dermatol Ther. 2021;34:e14691.
   PubMed Web of Science ®Google Scholar
• Pirro F, Caldarola G, Chiricozzi A, et al. The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies. J Dermatolog Treat. 2020; 1–5. doi: 10.1080/09546634.2020.1800578
   Web of Science ®Google Scholar
• Arnold T, Schaarschmidt ML, Herr R, et al. Drug survival rates and reasons for drug discontinuation in psoriasis. J Dtsch Dermatol Ges. 2016;14:1089–1099.
   PubMed Web of Science ®Google Scholar
• Richards HL, Fortune DG, O’Sullivan TM, et al. Psoriasis patients’ compliance with medication. J Am Acad Dermatol. 1999;41:581–583.
   PubMed Web of Science ®Google Scholar
• Zaghloul SS, Goodfield MJD. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140(4):408–414.
   PubMedGoogle Scholar
• Sanchez DP, Kirsner RS, Lev-Tov H. Clinical considerations for managing dermatology patients on systemic immunosuppressive or biologic therapy, or both, during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83:288–292.
   PubMed Web of Science ®Google Scholar
• Fleming P, Bai JW, Pratt M, et al. The prevalence of anx- iety in patients with psoriasis: a systematic review of observational studies and clinical trials. J Eur Acad Dermatol Venereol. 2017;31(5):798–807.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhao N. Generalized anxiety disorder, depressive symptoms and sleep quality during COVID-19 epidemic in China: a web-based cross-sectional survey. Psychiatry Res. 2020;288:112954.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, Chiricozzi A, et al. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study. Expert Opin Biol Ther. 2021;21:271–277.
   PubMed Web of Science ®Google Scholar
• Baniandrés-Rodríguez O, Vilar-Alejo J, Rivera R, et al. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis. J Am Acad Dermatol. 2021;84:513–517.
   PubMed Web of Science ®Google Scholar
• Hooijberg F, Boekel L, Vogelzang EH, et al. Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population. Lancet Rheumatol. 2020;2(10):e583–e585.
   PubMedGoogle Scholar
• Mahil SK, Dand N, Mason KJ, et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study. J Allergy Clin Immunol. 2021;147:60–71.
   PubMed Web of Science ®Google Scholar
• Rademaker M, Baker C, Foley P, et al. Advice regarding COVID‐19 and use of immunomodulators, in patients with severe dermatological diseases. Austral J Dermatol. 2020; 61:158–159.
   PubMed Web of Science ®Google Scholar
• Brazzelli V, Isoletta E, Barak O, et al. Does therapy with biological drugs influence COVID‐19 infection? Observational monocentric prevalence study on the clinical and epidemiological data of psoriatic patients treated with biological drugs or with topical drugs alone. Dermatol Ther. 2020;33:e14516.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Piaserico S, Naldi L, et al. Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: a Northern Italy experience. J Aller Clin Immunol. 2021;147:558–560.
   PubMed Web of Science ®Google Scholar